Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF Summary
Product Specifications
SARS-CoV-2 ORF7a (Glu16-Leu96) Accession # YP_009724395.1 | IEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10668-CV
Formulation | Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP and Glycerol. |
Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: ORF7a
Open Reading Frame 7a (ORF7a) is one of eight accessory proteins encoded at the 3' region of the coronavirus (CoV) genome (1). The accessory proteins are largely dispensable for viral replication and growth in vitro (2,3). Although not essential for replication the accessory proteins are thought to modulate virus-host interactions that are important during infection (4). Coronaviruses include various highly pathogenic strains such as SARS-CoV, MERS-CoV and SARS-CoV2 that have had significant impact on humans as well as strains that have negatively impacted livestock. ORF7a from SARS-CoV2 is a small 121 amino acid (aa) type I transmembrane protein (5,6). ORF7a contains an N-terminal signal peptide, a luminal domain, transmembrane domain, and a short C-terminal cytoplasmic tail that functions as an ER export signal (5,7). It is expressed and retained intracellularly in cells infected with SARS-CoV and primarily localized to the Golgi (5,7) Although the function of the accessory proteins has not been well-defined, ORF7a has been shown to activate p38 MAPK(7), NF-kB, and JNK signaling pathways, enhance production of inflammatory chemokines known to be upregulated in SARS-CoV infection (8), and inhibit cellular protein synthesis (9). These reports indicate ORF7a may be involved in the inflammatory response and induction of apoptosis of SARS-CoV infected cells (7-10). ORF7a has also been reported to bind and prevent glycosylation of host cell protein bone marrow stromal antigen 2 (BST-2). Binding inhibits BST-2's ability to block the release of SARS-CoV virions (11). Therapeutics designed to inhibit the interaction of the ectodomain of ORF7a and BST2 have been proposed as a method to inhibit virus growth (11).
- Hartenian, E. et al. (2020) J. Biol. Chem. 295:12910.
- Haijema, B.J. et al. (2004) J. Virol. 78:3863.
- Yount, B. et al. (2005) J. Virol. 79:14909.
- Liu, D.X. et al. (2014) Antiviral Res. 109:97.
- Nelson, C.A. et al. (2005) Structure 13:75.
- Yoshimoto, F.K. et al. (2020) Protein J. 39:198.
- Schaecher, S.R. et al. (2007) J. Virol. 81:11054.
- Kanzawa, N. et al. (2006) FEBS Lett. 580:6807.
- Kopecky-Bromberg, S.A. et al. (2006) J. Virol. 80:785.
- Tan, Y. et al. (2004) J. Virol. 78:14043.
- Taylor, J.K. et al. (2015) J. Virol. 89:11820.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image